METHODS

RESULTS

Patients

Treatment

Efficacy

safety profile, preliminary efficacy and PK characteristics of CTA1.

Key eligibility criteria (phase Ib)

Table´ overall

Table 2. Summary of AEs

Table 3. Most Common TRAEs of Any Grade and Grade 3/4

Demographics and Baseline Characteristics	Total (N = 14)

Figure 1. Best Change from Baseline in Target Lesions




Figure 2. Swimmer Plot of Patients





Figure 3. Kaplan-Meier Analysis of PFS



Figure 4. Kaplan-Meier Analysis of OS



Pharmacokinetics

Figur Ɛ

